HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Fontolizumab Protein Design Labs.

Abstract
Protein Design Labs is developing fontolizumab, a humanized anti-interferon gamma monoclonal antibody, for the potential treatment of autoimmune diseases. By February 2003, the company was actively seeking to outlicense the development and commercialization rights to fontolizumab outside of the US and Canada.
AuthorsFrancis J Dumont
JournalCurrent opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 6 Issue 5 Pg. 537-44 (May 2005) ISSN: 1472-4472 [Print] England
PMID15912969 (Publication Type: Journal Article, Review)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • fontolizumab
  • Interferon-gamma
Topics
  • Animals
  • Antibodies, Monoclonal (chemistry, therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Autoimmune Diseases (drug therapy)
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Drug Design
  • Drug Industry (organization & administration)
  • Humans
  • Interferon-gamma (antagonists & inhibitors, chemistry, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: